Answers are grounded in this paper and cite their sources.
Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) are novel high-cost treatments for the prevention of migraine. This study presents data on utilization, expenditure, and treatment patterns with CGRP mAbs available under a managed access protocol in Ireland, to a cohort of treatment refractory patients (failed 3 or more previous treatments) with chronic migraine.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: